Helix BioPharma Appoints General Counsel and VP of Clinical Operations to Bolster Leadership Ahead of U.S. Listing

Helix BioPharma Corp., a clinical-stage oncology company, announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, effective June 30, 2026. The moves are part of the company’s preparations for a planned U.S. securities exchange listing and the advancement of its lead drug candidate, L-DOS47, into a Phase IB/Randomized Phase II study for first-line non-small cell lung cancer (NSCLC).

CEO Thomas Mehrling emphasized that the company is evolving rapidly. ‘The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,’ he said. ‘As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization.’

Mehrling noted that the company is executing a clear capital markets roadmap, with the preparation of a base shelf prospectus underway and the auditor review of second-quarter financials completed. ‘Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution,’ he added.

Helen Middleton brings over 30 years of experience in pharmacy, law, and the global life sciences industry. A qualified life sciences lawyer and registered clinical pharmacist, she has held senior legal roles at Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam, and most recently served as Legal Consultant to Kyowa Kirin International. As General Counsel, she will oversee Helix’s legal affairs, governance, compliance, and strategic transactions, supporting the company’s clinical advancement and planned U.S. listing.

David Browning brings more than 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, and academic sectors. He has overseen more than 30 Phase I-III clinical studies spanning first-in-human studies through regulatory approval and has built global oncology clinical operations teams across North America, Europe, Latin America, South Africa, and the Asia-Pacific region. As Vice President of Clinical Operations, he will lead operational planning and execution for Helix’s clinical programs, including the LDOS007 study, while expanding operational capabilities for future pipeline growth.

The appointments underscore Helix’s commitment to building the legal, governance, and operational infrastructure required for its next phase of growth. The company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in NSCLC and shares its targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates in discovery. Additionally, the company is advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, a first-in-class oral gemcitabine prodrug.

Helix is listed on the TSX, OTC PINK, and Frankfurt Stock Exchange. More information is available at https://www.helixbiopharma.com/.

These leadership additions represent another important milestone as Helix prepares for its next phase of clinical development and capital markets execution, aiming to create long-term value for patients and shareholders.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Helix BioPharma Appoints General Counsel and VP of Clinical Operations to Bolster Leadership Ahead of U.S. Listing.

The post Helix BioPharma Appoints General Counsel and VP of Clinical Operations to Bolster Leadership Ahead of U.S. Listing appeared first on citybuzz.